Clinical Trial Update: Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating docetaxel and prednisone with or without vaccine therapy in metastatic hormone-resistant prostate cancer; the study is terminated with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-resistant Prostate Cancer
• Prostate Adenocarcinoma
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• PREDNISONE (Prednisone)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2014-07-23